ZC3H12A Inhibits Tumor Growth and Metastasis of Breast Cancer Under Hypoxic Condition Via the Inactivation of IL-17 Signaling Pathway

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2024 Feb 15

PMID 38357935

Authors

Zhongbing Luo

Fulan Yang

Kang Liu

Zhenluo Ding

Affiliations

Soon will be listed here.

Abstract

Hypoxia is a major contributor to tumor microenvironment (TME) and metastasis in most solid tumors. We seek to screen hypoxia-related genes affecting metastasis in breast cancer and to reveal relative potential regulatory pathway. Based on gene expression profiling of GSE17188 dataset, differential expressed genes (DEGs) were identified between highly metastatic breast cancer cells under hypoxia and samples under normoxia. The protein-protein interaction (PPI) network was utilized to determine hub genes. The gene expression profiling interactive analysis database (GEPIA2) and quantitative reverse-transcription polymerase chain reaction (qRT-PCR) were employed to quantify hub genes. Moreover, overexpression of zinc finger CCCH-type containing 12A (ZC3H12A) was performed both in breast cancer cells and xenograft mouse model to determine the role of ZC3H12A. We identified 134 DEGs between hypoxic and normoxic samples. Based on PPI analysis, 5 hub genes interleukin (IL)-6, GALN (GAL), CD22 molecule (CD22), ZC3H12A and TNF receptor associated factor 1 (TRAF1) were determined; the expression levels of TRAF1, IL-6, ZC3H12A and GAL were remarkably downregulated while CD22 was upregulated in breast cancer cells. Besides, patients with higher expression of ZC3H12A had favorable prognosis. Overexpression of ZC3H12A could inhibit metastasis and tumor growth of breast cancer; overexpression of ZC3H12A downregulated the expression of IL-17 signaling pathway-related proteins such as IL-17 receptor A (IL-17RA), IL-17A and nuclear factor κB activator 1 (Act1). This study reveals ZC3H12A and IL-17 signaling pathway as potential therapeutic targets for hypoxic breast cancer.

Citing Articles

RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway.

Xing S, Li D, Zhao Q Aging (Albany NY). 2024; 16(17):12392-12413.

PMID: 39207452 PMC: 11424578. DOI: 10.18632/aging.206096.

References

Gilkes D . Implications of Hypoxia in Breast Cancer Metastasis to Bone. Int J Mol Sci. 2016; 17(10). PMC: 5085702. DOI: 10.3390/ijms17101669. View

Somma D, Mastrovito P, Grieco M, Lavorgna A, Pignalosa A, Formisano L . CIKS/DDX3X interaction controls the stability of the Zc3h12a mRNA induced by IL-17. J Immunol. 2015; 194(7):3286-94. PMC: 4369453. DOI: 10.4049/jimmunol.1401589. View

Azimi I, Milevskiy M, Chalmers S, Yapa K, Robitaille M, Henry C . ORAI1 and ORAI3 in Breast Cancer Molecular Subtypes and the Identification of ORAI3 as a Hypoxia Sensitive Gene and a Regulator of Hypoxia Responses. Cancers (Basel). 2019; 11(2). PMC: 6406924. DOI: 10.3390/cancers11020208. View

Sun X, Luo H, Han C, Zhang Y, Yan C . Identification of a Hypoxia-Related Molecular Classification and Hypoxic Tumor Microenvironment Signature for Predicting the Prognosis of Patients with Triple-Negative Breast Cancer. Front Oncol. 2021; 11:700062. PMC: 8416750. DOI: 10.3389/fonc.2021.700062. View

Takeuchi O . Endonuclease Regnase-1/Monocyte chemotactic protein-1-induced protein-1 (MCPIP1) in controlling immune responses and beyond. Wiley Interdiscip Rev RNA. 2017; 9(1). DOI: 10.1002/wrna.1449. View

Wang J, Wang Y, Xing P, Liu Q, Zhang C, Sui Y . Development and validation of a hypoxia-related prognostic signature for breast cancer. Oncol Lett. 2020; 20(2):1906-1914. PMC: 7377061. DOI: 10.3892/ol.2020.11733. View

Lu X, Yan C, Yuan M, Wei Y, Hu G, Kang Y . In vivo dynamics and distinct functions of hypoxia in primary tumor growth and organotropic metastasis of breast cancer. Cancer Res. 2010; 70(10):3905-14. PMC: 2872139. DOI: 10.1158/0008-5472.CAN-09-3739. View

Shi R, Liao C, Zhang Q . Hypoxia-Driven Effects in Cancer: Characterization, Mechanisms, and Therapeutic Implications. Cells. 2021; 10(3). PMC: 8003323. DOI: 10.3390/cells10030678. View

Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M . Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022; 66:15-23. PMC: 9465273. DOI: 10.1016/j.breast.2022.08.010. View

10.

Zhang J, Zhang J, Xu S, Zhang X, Wang P, Wu H . Hypoxia-Induced TPM2 Methylation is Associated with Chemoresistance and Poor Prognosis in Breast Cancer. Cell Physiol Biochem. 2018; 45(2):692-705. DOI: 10.1159/000487162. View

11.

Chen A, Sceneay J, Godde N, Kinwel T, Ham S, Thompson E . Intermittent hypoxia induces a metastatic phenotype in breast cancer. Oncogene. 2018; 37(31):4214-4225. DOI: 10.1038/s41388-018-0259-3. View

12.

Hajizadeh F, Maleki L, Alexander M, Mikhailova M, Masjedi A, Ahmadpour M . Tumor-associated neutrophils as new players in immunosuppressive process of the tumor microenvironment in breast cancer. Life Sci. 2020; 264:118699. DOI: 10.1016/j.lfs.2020.118699. View

13.

Kotlinowski J, Hutsch T, Czyzynska-Cichon I, Wadowska M, Pydyn N, Jasztal A . Deletion of Mcpip1 in Mcpip1Alb mice recapitulates the phenotype of human primary biliary cholangitis. Biochim Biophys Acta Mol Basis Dis. 2021; 1867(5):166086. PMC: 8938941. DOI: 10.1016/j.bbadis.2021.166086. View

14.

Brahimi-Horn M, Chiche J, Pouyssegur J . Hypoxia and cancer. J Mol Med (Berl). 2007; 85(12):1301-7. DOI: 10.1007/s00109-007-0281-3. View

15.

Gorka J, Marona P, Kwapisz O, Rys J, Jura J, Miekus K . The anti-inflammatory protein MCPIP1 inhibits the development of ccRCC by maintaining high levels of tumour suppressors. Eur J Pharmacol. 2020; 888:173591. DOI: 10.1016/j.ejphar.2020.173591. View

16.

Garg A, Amatya N, Chen K, Cruz J, Grover P, Whibley N . MCPIP1 Endoribonuclease Activity Negatively Regulates Interleukin-17-Mediated Signaling and Inflammation. Immunity. 2015; 43(3):475-87. PMC: 4575280. DOI: 10.1016/j.immuni.2015.07.021. View

17.

Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A . STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2012; 41(Database issue):D808-15. PMC: 3531103. DOI: 10.1093/nar/gks1094. View

18.

Jinna N, Rida P, Smart M, LaBarge M, Jovanovic-Talisman T, Natarajan R . Adaptation to Hypoxia May Promote Therapeutic Resistance to Androgen Receptor Inhibition in Triple-Negative Breast Cancer. Int J Mol Sci. 2022; 23(16). PMC: 9408190. DOI: 10.3390/ijms23168844. View

19.

Emami Nejad A, Najafgholian S, Rostami A, Sistani A, Shojaeifar S, Esparvarinha M . The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell Int. 2021; 21(1):62. PMC: 7816485. DOI: 10.1186/s12935-020-01719-5. View

20.

Lyu J, Park D, Huang B, Kang S, Lee S, Lee C . RGS2 suppresses breast cancer cell growth via a MCPIP1-dependent pathway. J Cell Biochem. 2014; 116(2):260-7. DOI: 10.1002/jcb.24964. View